XML 132 R50.htm IDEA: XBRL DOCUMENT
v3.22.4

Other Consolidated Financial Statement Detail (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental cash flow information | Supplemental disclosure of cash flow information for the years ended December 31, 2022, 2021 and 2020, is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Cash paid during the year for: |  |  |  |  |  |
Interest |  | $ | 262.5 |  |  | $ | 280.8 |  |  | $ | 272.7 |
Income taxes |  | 932.9 |  |  | 247.9 |  |  | 906.7 |
Other income (expense), net | Components of other (income) expense, net, are summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Gain on sale of equity interest in Samsung Bioepis(1) |  | $ | (1,505.4) |  |  | $ | — |  |  | $ | — |
Litigation settlement agreement and settlement fees |  | 917.0 |  |  | — |  |  | — |
Interest income |  | (89.3) |  |  | (11.0) |  |  | (42.0) |
Interest expense |  | 246.6 |  |  | 253.6 |  |  | 222.5 |
(Gains) losses on investments, net |  | 277.3 |  |  | 824.9 |  |  | (685.7) |
Foreign exchange (gains) losses, net |  | 35.5 |  |  | 22.4 |  |  | 10.7 |
Other, net |  | 10.1 |  |  | 5.6 |  |  | (2.9) |
Total other (income) expense, net |  | $ | (108.2) |  |  | $ | 1,095.5 |  |  | $ | (497.4) |
(1) Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these consolidated financial statements.
Gain (loss) on investments | The following table summarizes our (gains) losses on investments, net that relates to our equity securities held as of December 31, 2022, 2021 and 2020:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Net (gains) losses recognized on equity securities |  | $ | 264.7 |  |  | $ | 821.1 |  |  | $ | (693.9) |
Less: Net (gains) losses realized on equity securities |  | — |  |  | (10.3) |  |  | (12.1) |
Unrealized (gains) losses recognized on equity securities |  | $ | 264.7 |  |  | $ | 831.4 |  |  | $ | (681.8) |
Accrued expense and other | Accrued expense and other consists of the following:
|  | As of December 31,
(In millions) |  | 2022 |  | 2021
Revenue-related reserves for discounts and allowances |  | $ | 891.6 |  |  | $ | 802.1 |
Employee compensation and benefits |  | 395.6 |  |  | 345.1 |
Collaboration expense |  | 277.9 |  |  | 324.7 |
Royalties and licensing fees |  | 209.4 |  |  | 234.7 |
Other |  | 746.9 |  |  | 828.6 |
Total accrued expense and other |  | $ | 2,521.4 |  |  | $ | 2,535.2 |

X
- Definition Tabular disclosure of realized and unrealized gain (loss) on investment in security. + References No definition available. + Details
Name: | us-gaap_GainLossOnInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accrued liabilities. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of supplemental cash flow information for the periods presented. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + References No definition available. + Details
Name: | us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration